Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Immune Checkpoint Blockade Activates Macrophages and Remodels the Lymph Node Microenvironment in Melanoma Metastasis

ABSTRACT: The factors that drive therapeutic resistance and variable patient response to immune checkpoint blockade therapies within the metastatic lymph nodes are poorly understood. Activation of lymph node immune cells can promote effective immune checkpoint blockade responses or alternately enforce immunosuppression. Here we investigated a murine model of lymph node melanoma metastasis that was amenable to combination immune checkpoint blockade at the cellular, protein, and transcriptional level. Checkpoint blockade spatially reorganized and activated T and B lymphocytes as well as lymph node stromal cells. Notably, myeloid cells, key mediators of lymph node immune function, were reprogrammed to an immunostimulatory phenotype upon checkpoint blockade. Our data supports a model in which immunostimulatory macrophages are induced and macrophage-mediated T cell suppression is released during effective immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE334818 | GEO | 2026/09/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Flt3L -expanded conventional type I dendritic cells formed in the tumor prime “stem-like” T cells in the draining lymph nodes to evoke enhanced responses to immunotherapy [2]

Project description:Immune checkpoint blockade (ICB) evokes anti-tumor immunity through the reinvigoration of tumor-specific T cell responses but it is only effective in a subset of patients. T cell differentiation status is a critical determinant of response, with less differentiated cells demonstrating an enhanced capacity to proliferate following ICB. Given recent data indicating that conventional type 1 dendritic cells (cDC1) maintain precursor exhausted (TPEX) cells, we hypothesized that expansion of cDC1s could enhance responses to ICB. Treatment of mice with Flt3L simultaneously expanded cDC1s and CD62L+SLAMF6+CD8+ T cells in both tumors and draining lymph nodes. The formation of these CD62L+SLAMF6+ CD8+ T cells is dependent on the transcription factor Myb, CCR7+ XCR1+DCs and lymph node egress. Hence, we demonstrate that the lymph node is a critical site for the effect of Flt3L on T cell differentiation state. We hypothesized that the promotion of this phenotype would enable more effective responses to ICB. Indeed, the combination of Flt3L and anti-CTLA4 led to significantly enhanced therapeutic responses and was associated with the emergence of a unique CD8+ T cell subset characterized by the expression of IL-21R.

2025-10-02 | GSE291948 | GEO

Flt3L -expanded conventional type I dendritic cells formed in the tumor prime “stem-like” T cells in the draining lymph nodes to evoke enhanced responses to immunotherapy [1]

2025-10-02 | GSE291668 | GEO

Liu2019 - Logistic Regression models to predict intrinsic resistance to anti-PD1 ICB in Ipilimumab treated and Ipilimumab naive patients with metastatic melanoma.

Project description:In this comprehensive study, the authors have developed concise models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 Immune Checkpoint Blockade (ICB) treatment in individual tumors. It's important to note that their validation was performed in smaller, independent cohorts, constrained by data availability. The authors have developed two Logistic Regression based models for Ipilimumab treated and Ipilimumab naive patients with metastatic melanoma. The main predictive features for the Ipilimumab treated patients are MHC-II HLA, LDH at treatment initiation and the presence of lymph node metastases (LN met), chosen using forward selection methodology. The main predictive features for the Ipilimumab naive patients are tumor heterogeneity, tumor ploidy and tumor purity, chosen using forward selection methodology. Please note that in these models, the output ‘1’ means progressive disease (PD) and ‘0’ means non-PD. The original GitHub repository can be accessed at https://github.com/vanallenlab/schadendorf-pd1

2023-11-17 | MODEL2310150001 | BioModels

CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses

Project description:The induction of proinflammatory T cells by dendritic cell (DC) subtypes is critical for anti-tumor responses and effective immune checkpoint blockade (ICB) therapy. Here we show that human CD1c+CD5+ dendritic cells are reduced in melanoma-affected lymph nodes, with CD5 expression on DCs correlating with patient survival. Activating CD5 on DCs enhanced T-cell priming and improved survival after immune checkpoint blockade therapy. CD5+ DC numbers increased during ICB treatment, and low IL-6 levels promoted their de novo differentiation. Mechanistically, CD5 expression by DCs was required to generate optimally protective CD5hi T helper and CD8+ T cells; further, deletion of CD5 from T cells dampened tumor elimination in response to ICB therapy in vivo. Thus, CD5+ dendritic cells are an essential component of optimal immune checkpoint blockade therapy.

2023-02-22 | GSE219197 | GEO

Project description:Polysaccharide nanoparticles initiate trained immunity through lymph node immune responses and synergistically eradicate tumours with innate immune checkpoint blockade

| PRJNA1142783 | ENA

Transcriptomic studies on ruxolitinib with or without checkpoint inhibitors as a cancer therapy

Project description:Unleashing anti-tumor T cell activity by checkpoint inhibition is effective in many cancer patients but clinical response rates remain limited. Myeloid derived suppressor cells erode antitumor lymphocyte numbers and function, and correlate with resistance to checkpoint inhibitors. By screening small molecule libraries, we identified JAK inhibitors’ ability to rescue T cell function. Despite its documented immune suppressive properties, the prototypical JAK inhibitor ruxolitinib enhanced the efficacy of immune checkpoint blockade in cancer. This effect correlated with loss of suppressive gene expression, and acquisition of immunostimulatory molecular markers and T cell stimulatory activity in myeloid cells. In preclinical models, ruxolitinib significantly improved the function and increased the total numbers of activated tumor-infiltrating NK and CD4 T cells compared to checkpoint blockade alone and the efficacy was conditional on granulocytic cells. In addition to myeloid reprogramming in the tumor, ruxolitinib blunts G-CSF signaling in the bone marrow to prevent expression of suppressive and chemotaxis genes in neutrophils.

2024-06-20 | GSE209647 | GEO

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

Project description:Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

| PRJNA858443 | ENA

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Synthesis [scRNAseq]

Project description:Therapeutic resistance to immune checkpoint blockade remains a prevalent obstacle across many cancer types, and an improved mechanistic understanding of this process could lead to effective combination treatments. Herein, we identify the Hedgehog transcription factor Gli2 as a key node of tumor-mediated immune evasion during mesenchymal transition via the production of Wnt ligands and prostaglandins. This promotes an immune microenvironment rich in PMN-MDSCs, while lacking antigen-presenting cDC1s and effector cells. Gli2-active tumors resist anti-PD-1 treatment, this can be overcome with inhibition of Wnt ligand secretion and selective prostaglandin receptor blockade. The identification of a Gli2 signature in patient samples provides a translational roadmap to direct precision combination immunotherapeutics in the clinic.

2025-02-05 | GSE279937 | GEO

Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses

Project description:The gut microbiome modulates immunotherapy treatment responses, and this may explain why immune checkpoint inhibitors (ICI), such as anti-PD-1, are only effective in some patients. Previous studies correlated lipopolysaccharide (LPS)-producing gut microbes with poorer prognosis; however, LPS from diverse bacterial species can range from immunostimulatory to inhibitory. By functionally analyzing fecal metagenomes from 112 melanoma patients, we found that a subset of LPS-producing bacteria encoding immunostimulatory hexa-acylated LPS was enriched in microbiomes of clinical responders. In an implanted tumor mouse model of anti-PD-1 treatment, microbiota-derived hexa-acylated LPS was required for effective anti-tumor immune responses, and LPS-binding antibiotics and a small molecule TLR4 antagonist abolished anti-PD-1 efficacy. Conversely, oral administration of hexa-acylated LPS to mice significantly augmented anti-PD-1-mediated anti-tumor immunity. Penta-acylated LPS did not improve anti-PD-1 efficacy in vivo and inhibited hexa-acylated LPS-induced immune activation in vitro. Microbiome hexa-acylated LPS therefore represents an accessible predictor and potential enhancer of immunotherapy responses.

2025-01-08 | MSV000096803 | MassIVE

scRNA-seq of myeloid cells from subcutaneous MC38-Ova tumours and draining lymph nodes (LN) in photoconvertible Kaede mice

Project description:We combined scRNA-seq and a photoconvertible mouse model to study the spatiotemporal dynamics of macrophages and dendritic cells (DCs) in murine tumours including their migration to the lymph node, including the effects of immune checkpoint therapy (anti-PD-L1).

2023-12-15 | GSE221513 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data